# SiteOne Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/siteone-therapeutics

- Industry: Biotechnology
- Headquarters: South San Francisco, US
- Website: www.site1therapeutics.com
- Total disclosed funding: $116M
- Latest round: Series C (Dec 18, 2024)
- Investors on record: 12

## About

SiteOne Therapeutics, Inc., based in South San Francisco, specializes in innovative therapeutic solutions aimed at addressing unmet medical needs in healthcare, focusing on advanced drug delivery and targeted therapies.Founded in 2010, SiteOne Therapeutics, Inc. operates as a biomedical company dedicated to developing therapies for sensory hyperexcitability disorders. The company has undergone strategic pivots to enhance its focus on targeted small molecule ion channel modulators. The firm is headquartered in South San Francisco, US, and has successfully completed a total of 6 deals, with its most recent funding round occurring on December 18, 2024. SiteOne Therapeutics raised USD 100.00 mn in its Series C funding led by Novo Holdings, with participation from additional investors including OrbiMed Advisors and Wellington Management. The total amount raised by the company stands at USD 100.00 mn, with a current valuation of USD 135.60 mn. The CEO of the company is John Mulcahy, and it was founded by Sandip Biswal.SiteOne Therapeutics specializes in developing innovative therapeutic solutions for unmet medical needs in the healthcare sector. The company primarily offers advanced drug delivery systems and targeted therapies aimed at enhancing treatment efficacy for chronic pain and neurological disorders. Their products utilize technology to improve patient outcomes, primarily serving hospitals, healthcare providers, and specialty pharmacies in North America and Europe.SiteOne Therapeutics generates revenue through a structured business model that includes partnerships with healthcare providers, wholesalers, and direct-to-consumer sales channels. The firm engages in B2B transactions, supplying core therapeutic products to hospitals and clinics while exploring subscription models for ongoing access to their therapies. Customers typically enter into agreements for bulk purchasing, facilitating streamlined access to the company's offerings.With the recent Series C funding of USD 100.00 mn secured on December 18, 2024, SiteOne Therapeutics plans to advance its innovative range of targeted, small molecule ion channel modulators aimed at treating sensory hyperexcitability disorders through essential human clinical validation. The funding will drive the development of upcoming products and assist in the company's strategic expansion into new markets, though specific regions have yet to be disclosed.

## Funding rounds

- Series C, Dec 18, 2024, $100M — OrbiMed Advisors, Novo Holdings, Wellington Management, Mission Biocapital, Bsquared Capital
- Series B, Dec 21, 2016, $15M — Amgen Ventures, Mission Bay Capital, Sears Capital Management, 2M Companies, BioBrit, Next Frontier Capital, Z Investment Partners
- Series A, Jul 2, 2015, $1.3M — Mission Bay Capital, Sears Capital Management, 2M Companies, BioBrit, Next Frontier Capital, Z Investment Partners

## Investors

- Mission Bay Capital (https://capitalatlas.ai/funds/mission-bay-capital) — Series A, Series B
- Sears Capital Management (https://capitalatlas.ai/funds/sears-capital-management) — Series A, Series B
- 2M Companies (https://capitalatlas.ai/funds/2m-companies) — Series A, Series B
- BioBrit — Series A, Series B
- Next Frontier Capital (https://capitalatlas.ai/funds/next-frontier-capital) — Series A, Series B
- Z Investment Partners (https://capitalatlas.ai/funds/z-investment-partners) — Series A, Series B
- Amgen Ventures (https://capitalatlas.ai/funds/amgen-ventures) — Series B
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series C
- Novo Holdings — Series C
- Wellington Management (https://capitalatlas.ai/funds/wellington-management) — Series C
- Mission Biocapital (https://capitalatlas.ai/funds/mission-biocapital) — Series C
- Bsquared Capital — Series C